Axios @axios
The FDA has asked Pfizer to investigate whether a second five-day course of the drug will prevent the virus from returning. Pfizer executives in May suggested patients who can't clear the virus with the first course should take more, Bloomberg reported. https://t.co/fxiAnLSFZh — PolitiTweet.org